
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
More than 20% of prescriptions issued for children at 2 pediatric care sites during a 26-month period went unfilled, according to a retrospective review of claims data.






